1. Byham-Gray LD. Diabetic kidney disease. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

2. Burrows NR, Hora I, Geiss LS, Gregg EW, Albright A. Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes—United States and Puerto Rico, 2000–2014. MMWR. 2017;66(43):1165-1170.

3. United States Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States. Available at https://adr.usrds.org/2020. Last accessed November 1, 2021.

4. Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 4th ed. Chicago, IL: American Association of Diabetes Educators; 2017.

5. Westerfield J, Holcomb S, Jensen S (eds). Current Trends in Diabetes Management: A Guide for the Healthcare Professional. 7th ed. Nashville, TN: Healthways; 2008.

6. Bardsley JK, Magee MF. Pathophysiology of the metabolic disorder. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

7. American Diabetes Association. Fast Facts: Data and Statistics About Diabetes. Available at https://professional.diabetes.org/sites/professional.diabetes.org/files/media/sci_2020_diabetes_fast_facts_sheet_final.pdf. Last accessed November 1, 2021.

8. Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes: Principles and Practice. 2nd ed. New York, NY: Informa Healthcare; 2008.

9. Centers for Disease Control and Prevention. United States Diabetes Surveillance System. Diagnosed Diabetes. Available athttps://gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html. Last accessed November 1, 2021.

10. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Available at https://www.cdc.gov/diabetes/data/statistics-report/index.html. Last accessed November 1, 2021.

11. National Indian Council on Aging. Diabetes Still Highest Among AI/AN. Available at https://www.nicoa.org/diabetes-still-highest-among-ai-an. Last accessed November 1, 2021.

12. Colberg S, Friesz M. Diabetes Free Kids: A Take Charge Plan for Preventing and Treating Type 2 Diabetes in Children. New York, NY: Avery; 2005.

13. American Diabetes Association. Gestational Diabetes. Available at https://www.diabetes.org/diabetes/gestational-diabetes. Last accessed November 1, 2021.

14. Childs BP, Cypress M, Spollett G (eds). Complete Nurse's Guide to Diabetes Care. 2nd ed. Alexandria, VA: American Diabetes Association; 2009.

15. Tucker ME. USPSTF: Screen Everyone 45 and Older for Abnormal Glucose. Available at https://www.medscape.com/viewarticle/832850. Last accessed November 1, 2021.

16. U.S. Preventive Services Task Force. Final Recommendation Statement: Prediabetes and Type 2 Diabetes: Screening. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-for-prediabetes-and-type-2-diabetes. Last accessed November 1, 2021.

17. American Diabetes Association. Standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Suppl 1):S1-S232.

18. American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.

19. Edelman SV, Henry RR. Diagnosis and Management of Type 2 Diabetes. 12th ed. New York, NY: Professional Communications, Inc.: 2013.

20. Venes D (ed). Taber's Cyclopedic Medical Dictionary. 23rd ed. Philadelphia, PA: FA Davis Company; 2017.

21. PerlmanRL, Heung M, Ix JH. Renal disease. In: McPhee SJ, Lingappa VR, Ganong WF (eds). Pathophysiology of Disease: An Introduction to Clinical Medicine. 7th ed. New York, NY: McGraw Hill; 2014.

22. Lyn S. Smart Charts: Physiology. New York, NY: Lange; 2004.

23. Urden L, Stacy K, Lough M. Critical Care Nursing: Diagnosis and Management. 8th ed. St. Louis, MO: Mosby; 2017.

24. Huether SE, McCance KL (eds). Understanding Pathophysiology. 6th ed. St. Louis, MO: Elsevier; 2016.

25. Mindell JA, Chertow GM. A practical approach to acute renal failure. Med Clin North Am. 1997;81(3):731-748.

26. Workeneh BT, Agraharkar M, Gupta R. Acute Kidney Injury. Available at https://emedicine.medscape.com/article/243492-overview. Last accessed November 1, 2021.

27. Levine DZ. Caring for the Renal Patient. 3rd ed. Philadelphia, PA: Saunders; 1997.

28. Baumgarten M, Gehr T. Chronic kidney disease: detection and evaluation. Am Fam Physician. 2011;84(10):1138-1148.

29. Barri Y, Golper TA. Unique Aspects of Gastrointestinal Disease in Dialysis Patients. Available at https://www.uptodate.com/contents/unique-aspects-of-gastrointestinal-disease-in-dialysis-patients. Last accessed November 1, 2021.

30. Bloomgarden ZT. Diabetic nephropathy. Diabetes Care. 2008;31(4):823-827.

31. Basi S, Fesler P, Mimran A, Lewis JB. Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander? Diabetes Care. 2008;31(Suppl 2):S194-S201.

32. Ossman SS. Diabetic nephropathy: where we have been and where we are going. Diabetes Spec. 2006;19(3):153-156.

33. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556-563.

34. Maahs DM, Snively BM, Bell RA, et al. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care. 2007;30(10):2593-2598.

35. Taniwaki H, Nishizawa Y, Kawagishi T, et al. Decrease in glomerular filtration rate in Japanese patients with type 2 diabetes is linked to atherosclerosis. Diabetes Care. 1998;21(11):1848-1855.

36. Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35(10):2061-2068.

37. Premaratne E, Verma S, Ekinci EI, Theverkalam G, Jerums G, Maclsaac RJ. The impact of hyperfiltration on the diabetic kidney. Diabetes Metab. 2015;41(1):5-17.

38. Paige NM, Nagami GT. The top 10 things nephrologists wish every primary care physician knew. Mayo Clin Proc. 2009;84(2):180-186.

39. Heintz B, Stöcker G, Mrowka C, et al. Decreased glomerular basement membrane heparan sulfate proteoglycan in essential hypertension. Hypertension. 1995;25(3):399-407.

40. Mogensen CE. Renal dysfunction and hypertension. In: Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes: Principles and Practices. 2nd ed. New York, NY: Informa; 2008: 263-276.

41. Diabetes in Control. ADA Standards Highlight GFR Screening for Nephropathy. Available at https://www.diabetesincontrol.com/ada-standards-highlight-gfr-screening-for-nephropathy/. Last accessed November 1, 2021.

42. Xiang J, Morgenstern H, Li Y, Robinson BM, Herman WH, Saran R. Incidence of ESKD among Native Hawaiians and Pacific Islanders living in the 50 US states and Pacific Island territories. Am J Kidney Dis. 2020;76(3):P340-P349.

43. Stults B, Jones RE. Management of hypertension in diabetes. Diabetes Spectrum. 2006;19(1):25-31.

44. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55(6):1832-1839.

45. U.S. Food and Drug Administration. FDA Drug Safety Communication: New Warnings for Using Gadolinium-Based Contrast Agents in Patients with Kidney Dysfunction. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-warnings-using-gadolinium-based-contrast-agents-patients-kidney. Last accessed November 1, 2021.

46. Brown J, Thompson C. Contrast-induced acute kidney injury: the at-risk patient and protective measures. Curr Cardiol Rep. 2010;12(5):440-445.

47. Basu A. Contrast-Induced Nephropathy. Available at https://emedicine.medscape.com/article/246751-overview. Last accessed November 1, 2021.

48. Herrada B, Agarwal J, Abcar AC. How can we reduce the incidence of contrast-induced acute renal failure? Perm J. 2005;9(3):58-60.

49. National Kidney Foundation. Contrast Dye and the Kidneys. Available at https://www.kidney.org/atoz/content/Contrast-Dye- and-Kidneys. Last accessed November 1, 2021.

50. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.

51. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 2002;17(1):S29-S36.

52. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.

53. Cornell S, Sisson, E.M. Pharmacotherapy: dyslipidemia and hypertension in persons with diabetes. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

54. Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-176.

55. Dinwiddie LC, Burrows-Hudson S, Peacock EJ. Stage 4 chronic kidney disease: preserving kidney function and preparing patients for stage 5 kidney disease. Am J Nurs. 2006;106(9):40-51.

56. Kidney Disease Outcomes Quality Initiative. Clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471-530.

57. Akizawa T, Gejyo F, Nish S, et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Ther Apher Dial. 2011;15(5):431-440.

58. U.S. Food and Drug Administration. Drugs. Available at https://www.fda.gov/drugs. Last accessed November 1, 2021.

59. U.S. Food and Drug Administration. FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-modified-dosing-recommendations-improve-safe-use-erythropoiesis. Last accessed November 1, 2021.

60. Lexicomp Online. Available at https://online.lexi.com. Last accessed November 1, 2021.

61. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2019;73(3 Suppl 1):A7-A8.

62. KDOQI Clinical Practice Guidelines for vascular access. Am J Kidney Dis. 2006;48(Suppl 1):S176-S247.

63. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1-S164.

64. Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL. Brenner and Rector's The Kidney. 10th ed. Philadelphia, PA: Saunders; 2015.

65. Beathard G. A practitioner's resource guide to hemodialysis arteriovenous fistulas. ESRD Network Tex. 2003;(Suppl).

66. Lomonte C, Basile C. Preoperative assessment and planning of hemodialysis vascular access. Clin Kidney J. 2015;8(3):278-281.

67. Santoro D, Benedetto F, Mondello P, et al. Vascular access for hemodialysis: current perspectives. Int J Nephrol Renovasc Dis. 2014;7:284-294.

68. Drew DA, Lok CE. Strategies for planning the optimal dialysis access for an individual patient. Curr Opin Nephrol Hypertens. 2014;23(3):314-320.

69. Tordoir JH, Bode AS, van Loon MM. Preferred strategy for hemodialysis in access creation in elderly patients. Eur J Vasc Endovasc Surg. 2015;49(6):738-743.

70. Mansilla AV, Toombs BD, Vaughn WK, Zeledon JI. Patency and life-spans of failing hemodialysis grafts in patients undergoing repeated percutaneous de-clotting. Tex Heart Inst J. 2001;28(4):249-253.

71. Zaleski G. Declotting, maintenance, and avoiding procedural complications of native arteriovenous fistulae. Semin Intervent Radiol. 2004;21(2):83-93.

72. Centers for Medicare and Medicaid Services. Center for Clinical Standards and Quality. CMS ESRD Measured Manual for the 2018 Performance Period/2020 Payment Year v3.0. Available at https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/ESRDQIP/Downloads/ESRD-Manual-v30.pdf. Last accessed November 1, 2021.

73. Bloomgarden ZT. Inpatient diabetes control: rationale. Diabetes Care. 2004;27(8):2074-2080.

74. Guest S, Akonur A, Ghaffari A, Sloand J, Leypoldt JK. Intermittent peritoneal dialysis: urea kinetic modeling and implications of residual kidney function. Perit Dial Int. 2012;32(2):142-148.

75. Asghar RB, Bandyopadhay S, Woywodt A. Intermittent peritoneal dialysis: just enough for some or inadequate altogether? Perit Dial Int. 2012;32(2):134-136.

76. Organ Procurement and Transplantation Network. Policies: Allocation of Kidneys. Available at https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf. Last accessed November 1, 2021.

77. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011;86(5):444-456.

78. U.S. Department of Health and Human Services. America's Health Literacy: Why We Need Accessible Health Information. Available at https://www.ahrq.gov/sites/default/files/wysiwyg/health-literacy/dhhs-2008-issue-brief.pdf. Last accessed November 1, 2021.

79. ElSayed NA, Aleppo G, Aroda VR, et al. Chronic kidney disease and risk management: Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(Supplement_1):S191-S202.